PLRX — Pliant Therapeutics Share News
0.000.00%
Last trade - 00:00- $50.52m
- -$107.59m
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals
U.S. STOCKS ON THE MOVE-BioMarin Pharmaceutical, Home Depot, Klarna Group
U.S. STOCKS ON THE MOVE-EyePoint Inc, Amer Sports, Pliant Therapeutics
Pliant rises after FDA grants fast-track tag to experimental cancer drug
Brief: Pliant Therapeutics Receives FDA Fast Track Designation For PLN-101095 In Combination With Pembrolizumab For The Treatment Of Ici-Refractory Solid Tumors
Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount
Brief: Pliant Therapeutics Q2 Net Income USD -22.371 Million
Pliant Therapeutics, Inc. expected to post a loss of 34 cents a share - Earnings Preview
Pliant Therapeutics Q1 net loss narrows on lower expenses
Brief: Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed
Brief: Pliant Therapeutics Announces Upcoming Presentation Of Phase 1 Clinical Trial Of PLN-101095 In Patients With Solid Tumors At The 2026 Aacr Annual Meeting
Pliant Therapeutics Q4 net loss narrows on lower costs
Brief: Pliant Therapeutics Q4 Net Income USD -23.577 Million
Brief: Pliant Therapeutics Announces Interim Data From PLN-101095
Pliant Therapeutics Q3 net loss narrows to $26.3 mln
Brief: Pliant Therapeutics Q3 Net Income USD -26.301 Million